<DOC>
	<DOCNO>NCT00424892</DOCNO>
	<brief_summary>The primary objective evaluate long-term safety desvenlafaxine succinate sustained-release ( DVS SR ) open-label treatment adult outpatient fibromyalgia syndrome .</brief_summary>
	<brief_title>Study Evaluating DVS SR Patients With Fibromyalgia Syndrome</brief_title>
	<detailed_description>Patients complete study 3151A4-327 opportunity treat DVS SR 6 month extension study .</detailed_description>
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<mesh_term>Desvenlafaxine Succinate</mesh_term>
	<criteria>Outpatients complete doubleblind treatment study 3151A4327 fibromyalgia Syndrome major protocol violation event would preclude patient 's entry longterm openlabel study . Women childbearing potential must negative serum pregnancy test result study start . Exclusion criterion : Presence new/and clinically important medical condition might compromise patient 's safety . Use prohibit treatment . Meets exclusion criterion list study 3151A4327 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
</DOC>